Business Description
Arcede Pharma AB
ISIN : SE0018168742
Compare
Compare
Traded in other countries / regions
Z61.GermanyARCEDE.Sweden IPO Date
2023-01-02Description
Arcede Pharma AB develops new patent-protected drug candidates with focus on chronic obstructive pulmonary disease and severe asthma with the aim to improve quality of life, reduce suffering and prolong life expectancy.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | N/A |
N/A
|
N/A
| |||
| Equity-to-Asset | 0.93 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -3.7 | |||||
| Beneish M-Score | -7.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Book Growth Rate | 463.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.76 | |||||
| 9-Day RSI | 36.58 | |||||
| 14-Day RSI | 37.86 | |||||
| 6-1 Month Momentum % | -85.71 | |||||
| 12-1 Month Momentum % | -92.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.23 | |||||
| Quick Ratio | 3.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.8 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 192.96 | |||||
| Operating Margin % | -43469.01 | |||||
| Net Margin % | -43467.61 | |||||
| FCF Margin % | -18600 | |||||
| ROE % | -89.56 | |||||
| ROA % | -81.52 | |||||
| ROIC % | -82.64 | |||||
| ROC (Joel Greenblatt) % | -502.03 | |||||
| ROCE % | -89.53 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.12 | |||||
| PB Ratio | 0.02 | |||||
| Price-to-Free-Cash-Flow | 0.04 | |||||
| Price-to-Operating-Cash-Flow | 0.04 | |||||
| EV-to-EBIT | -0.02 | |||||
| EV-to-EBITDA | -0.07 | |||||
| EV-to-Revenue | 6.66 | |||||
| EV-to-FCF | -0.06 | |||||
| Earnings Yield (Greenblatt) % | -5000 | |||||
| FCF Yield % | -1755.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arcede Pharma AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.004 | ||
| EPS (TTM) (€) | -0.032 | ||
| Beta | 0 | ||
| Volatility % | 331.7 | ||
| 14-Day RSI | 37.86 | ||
| 14-Day ATR (€) | 0.000316 | ||
| 20-Day SMA (€) | 0.00051 | ||
| 12-1 Month Momentum % | -92.15 | ||
| 52-Week Range (€) | 0.0002 - 0.0462 | ||
| Shares Outstanding (Mil) | 168.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arcede Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arcede Pharma AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arcede Pharma AB Frequently Asked Questions
What is Arcede Pharma AB(FRA:Z61)'s stock price today?
The current price of FRA:Z61 is €0.00. The 52 week high of FRA:Z61 is €0.05 and 52 week low is €0.00.
When is next earnings date of Arcede Pharma AB(FRA:Z61)?
The next earnings date of Arcede Pharma AB(FRA:Z61) is 2025-02-12 Est..
Does Arcede Pharma AB(FRA:Z61) pay dividends? If so, how much?
Arcede Pharma AB(FRA:Z61) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers